Valeant Pharma Announces Exercise Of Over-Allotment Option - Quick Facts

Valeant Pharma Announces Exercise Of Over-Allotment Option - Quick Facts

Valeant Pharmaceuticals International Inc. (VRX, VRX.TO) said Thursday that the underwriters of its recently priced public offering of common shares have exercised their option to purchase additional common shares and will purchase an additional about 3.53 million common shares at a price of $85.00 per share.

The option to purchase Additional Shares was granted pursuant to the Offering of approximately 23.53 million common shares at a price of $85.00 per share. The gross proceeds from the exercise of the option to purchase Additional Shares will total approximately $300 million, increasing the size of the Offering to approximately $2.3 billion. Closing of the Offering is expected to occur on or about June 24, 2013.

The company noted that it intends to use the net proceeds from the Firm Shares sold in the Offering, together with its previously announced debt financing, to fund (i) the consideration of its previously disclosed acquisition of Bausch + Lomb Holdings Incorporated or "B+L", (ii) the fees and expenses incurred in connection with the Merger; and (iii) the repayment or retirement of B+L's outstanding debt.

The company said it may use the proceeds from the Additional Shares sold in the Offering for general corporate purposes. If the Merger were not to close for any reason, the proceeds of the Offering, including the proceeds from such Additional Shares sold, will be used for general corporate purposes, which may include providing working capital, funding capital expenditures or for making one or more future acquisitions.

Goldman, Sachs & Co. will act as sole manager of the Offering outside of Canada and Goldman Sachs Canada Inc. will act as sole manager of the Offering in Canada.

For comments and feedback: contact [email protected]

http://www.rttnews.com

Suggested Articles

China's role as a major producer of global API has come under scrutiny, but so far global tensions haven't affected supply, the FDA said.

Reblozyl, a key drug in Bristol Myers Squibb's Celgene merger, has won a key FDA nod to treat patients with myelodysplastic syndromes.

Wealthy individuals typically don't set out to waste billions of dollars, but amid the COVID-19 pandemic, that’s exactly what Bill Gates plans to do.